Welcome to our dedicated page for Pasithea Therapeutics Warrants news (Ticker: KTTAW), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics Warrants stock.
Pasithea Therapeutics Corp is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. Leveraging expertise in neuroscience, translational medicine, and drug development, the company's pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
FAQ
What is the current stock price of Pasithea Therapeutics Warrants (KTTAW)?
What is Pasithea Therapeutics Corp focused on?
What is included in Pasithea Therapeutics Corp's pipeline?
What areas of expertise does Pasithea Therapeutics Corp leverage?
Who can be contacted for corporate communications at Pasithea Therapeutics Corp?
When is the initial safety, tolerability, and biomarker data expected to be reported?
When is the initial interim safety and PK data release on track for?
What diseases does Pasithea Therapeutics Corp focus on?
What is Pasithea Therapeutics Corp's primary area of research?
What is the core mission of Pasithea Therapeutics Corp?